Research Atlas · source screening

Carfilzomib

An attributable first-pass index of PubMed records whose titles name this governed identity. Records are sorted by publication date, not by evidence strength. Inclusion does not establish efficacy, safety, or a clinical indication.

Scope: Single-source, name-in-title discovery sample. Not a systematic review, worldwide source coverage, clinical appraisal, efficacy or safety conclusion, or complete WPF profile. This source index is separate from the Public Peptide Directory and from human observations.

Title-search results: 834
Shown with stable PMIDs: 25
Search recorded: 2026-09-26

Source: NCBI PubMed / MEDLINE · exact query: "Carfilzomib"[Title] · up to 25 recent title matches per identity. Each result links to its PubMed record.

Carfilzomib plus induction chemotherapy for children with relapsed or refractory acute lymphoblastic leukemia.
Blood Adv · 2026 Oct 13 · PMID 42234929 · DOI 10.1182/bloodadvances.2025019356
Source metadata only · evidence grade unassigned · scientific conclusions pending review
RETRACTION: Implications and Hidden Toxicity of Cardiometabolic Syndrome and Early-Stage Heart Failure in Carfilzomib-Induced Cardiotoxicity.
Br J Pharmacol · 2026 Sep 22 · PMID 42773391 · DOI 10.1111/bph.70699
Source metadata only · evidence grade unassigned · scientific conclusions pending review
MRD-guided induction-intensification with daratumumab-carfilzomib-based regimen followed by ASCT in patients with newly diagnosed multiple myeloma.
Leuk Lymphoma · 2026 Sep 6 · PMID 42702057 · DOI 10.1080/10428194.2026.2723847
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) induction prior to autologous haematopoietic stem cell transplant/transplantation in newly diagnosed multiple myeloma.
Br J Haematol · 2026 Sep · PMID 42403116 · DOI 10.1111/bjh.70642
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Real-world efficacy and safety of the carfilzomib-pomalidomide-dexamethasone regimen in patients with relapsed/refractory multiple myeloma: A multicenter retrospective study.
Ther Adv Hematol · 2026 · PMID 42661910 · DOI 10.1177/20406207261481202
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Incidence and Associated Risk Factors in the Development of Carfilzomib-Induced Cardiovascular Toxicity.
Curr Oncol · 2026 Aug 8 · PMID 42645376 · DOI 10.3390/curroncol33080471
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Risk factors for carfilzomib-related cardiovascular adverse events in Chinese patients with multiple myeloma: A real-world retrospective cohort study.
J Int Med Res · 2026 Aug · PMID 42622635 · DOI 10.1177/03000605261476840
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Design, radiolabeling, and biological evaluation of a novel (177)Lu-AAZTA(5)-Carfilzomib conjugate as a proteasome-targeted theranostic agent for multiple myeloma.
J Pharm Sci · 2026 Aug · PMID 42202909 · DOI 10.1016/j.xphs.2026.104347
Source metadata only · evidence grade unassigned · scientific conclusions pending review
The Association of Age and Frailty With Adverse Events for Bortezomib and Carfilzomib: A Population-Based Analysis.
Am J Hematol · 2026 Aug · PMID 42062824 · DOI 10.1002/ajh.70349
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Carfilzomib-induced severe pulmonary interstitial injury.
Ir J Med Sci · 2026 Aug · PMID 42043477 · DOI 10.1007/s11845-026-04349-4
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial.
Lancet · 2026 Jul 18 · PMID 42289183 · DOI 10.1016/S0140-6736(26)01088-3
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Comparison of adverse event profiles of carfilzomib-, elotuzumab-, and ixazomib-based therapies combined with lenalidomide and dexamethasone in patients with multiple myeloma using VigiBase.
Leuk Res · 2026 Jul · PMID 42001677 · DOI 10.1016/j.leukres.2026.108236
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Real-world effectiveness and safety of carfilzomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma: a retrospective analysis from China.
Front Oncol · 2026 · PMID 42394711 · DOI 10.3389/fonc.2026.1687341
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Carfilzomib Induces Cardiotoxicity by Blocking Autophagic Flux Through the cGAS-STING Signaling Pathway.
Biomolecules · 2026 Jun 11 · PMID 42352320 · DOI 10.3390/biom16060854
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Plain language summary of publication of how long people with relapsed multiple myeloma lived after treatment in the IKEMA study: Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone.
Future Oncol · 2026 Jun · PMID 42363804 · DOI 10.1080/14796694.2026.2683336
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Causal Effects of Hydrophilic Bile Acids on Carfilzomib-Related Cardiovascular Events in Multiple Myeloma: A Mendelian Randomization Study.
Clin Pharmacol Ther · 2026 Jun · PMID 41622719 · DOI 10.1002/cpt.70222
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Development and Validation of a Rapid LC-MS/MS Method for Carfilzomib Quantification in Plasma from Multiple Myeloma Patients.
J Vis Exp · 2026 May 12 · PMID 42224244 · DOI 10.3791/70167
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Belantamab mafodotin, carfilzomib, lenalidomide, and dexamethasone for relapsed or refractory multiple myeloma.
Blood Adv · 2026 May 12 · PMID 41719502 · DOI 10.1182/bloodadvances.2025019050
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Proteasome Targeting with Carfilzomib Induces Reactive Oxygen Species-Mediated Apoptosis in Hepatoblastoma.
Cells · 2026 May 9 · PMID 42193875 · DOI 10.3390/cells15100864
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Correction to 'Mucin 20 Modulates Proteasome Capacity Through c-Met Signalling to Increase Carfilzomib Sensitivity in Mantle Cell Lymphoma'.
J Cell Mol Med · 2026 May · PMID 42152608 · DOI 10.1111/jcmm.71186
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial.
Nat Med · 2026 May · PMID 41942646 · DOI 10.1038/s41591-026-04282-0
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Preferred standard-of-care carfilzomib dosing in multiple myeloma: An international survey of haematologists/oncologists.
Br J Haematol · 2026 May · PMID 41841734 · DOI 10.1111/bjh.70435
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Promoter hypomethylation drives ABCB1-mediated carfilzomib resistance in multiple myeloma.
Clin Epigenetics · 2026 Apr 1 · PMID 41923105 · DOI 10.1186/s13148-026-02115-y
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial.
Lancet Haematol · 2026 Apr · PMID 41831471 · DOI 10.1016/S2352-3026(26)00011-6
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Carfilzomib-Induced Cardiogenic Shock: A Reversible But Life-Threatening Complication.
Circ Heart Fail · 2026 Apr · PMID 41674458 · DOI 10.1161/CIRCHEARTFAILURE.125.013896
Source metadata only · evidence grade unassigned · scientific conclusions pending review

Loading research intelligence

Preparing the structured Flagship evidence library.